This substantially exceeds the expected survival time
of about 15 months even for regular GBM patients without early tumor recurrence.
A distribution function f(t) can be calculated from F(t) to determine the probability of observing survival time
up to t.
After treatment, the median progression-free survival time
was seven weeks for the chemotherapy group, but this more than doubled to 15.
This volume presents a rationale for the practices of drug development from drug company and regulatory agency perspectives, addressing such issues as the impact of adaptive designs on the quality of drugs that receive marketing approval, the design of Phase 3 studies that permit data-driven adjustment of the treatment effect estimate, the proper information for assessing whether a drug increases survival time
for the whole patient population, etc.
Therefore, our primary purpose was to explore the feasibility of using the TT in large surveys designed to assess Medicare beneficiaries' attitudes toward end-of-life options, in terms of a particularly salient attribute: the survival time
that could be offered by such options.
A clinical trial has shown that addition of chemotherapy to radiation therapy leads to a near doubling of median survival time
in patients with a form of brain tumor (oligodendroglioma) that carries a chromosomal abnormality called the 1p19q co-deletion.
The Macmillan Cancer Support charity said that the mean survival time
- the time from diagnosis until fewer than half of patients are still alive - has increased from one year to 5.
But progress has been woefully slow for lung and stomach cancer, where survival time
has hardly improved at all.
However the data also shows that for nine cancers, median survival time
Background: Studies reveal that cancer patients are actively seeking treatments and coping strategies which might be helpful to extend survival time
A report on two meta-analyses of stage II and III operable non-small cell lung cancers treated with surgery with or without chemotherapy reported that postoperative chemotherapy improved the five-year survival rate, recurrence-free survival time
to localized recurrence, and time to distant recurrence.
Washington, Oct 11 (ANI): Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time
when tumour treating fields (TTF) therapy was added to chemotherapy, as compared to chemotherapy alone.